DK2903600T3 - Virusholdig formulering og anvendelse deraf - Google Patents
Virusholdig formulering og anvendelse deraf Download PDFInfo
- Publication number
- DK2903600T3 DK2903600T3 DK13776991.5T DK13776991T DK2903600T3 DK 2903600 T3 DK2903600 T3 DK 2903600T3 DK 13776991 T DK13776991 T DK 13776991T DK 2903600 T3 DK2903600 T3 DK 2903600T3
- Authority
- DK
- Denmark
- Prior art keywords
- viral formulation
- viral
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306198 | 2012-10-02 | ||
| PCT/EP2013/070590 WO2014053571A1 (en) | 2012-10-02 | 2013-10-02 | Virus-containing formulation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2903600T3 true DK2903600T3 (da) | 2022-09-26 |
Family
ID=47018930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13776991.5T DK2903600T3 (da) | 2012-10-02 | 2013-10-02 | Virusholdig formulering og anvendelse deraf |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10111947B2 (da) |
| EP (1) | EP2903600B1 (da) |
| JP (1) | JP6466332B2 (da) |
| KR (1) | KR102181658B1 (da) |
| CN (1) | CN104797242B (da) |
| AU (1) | AU2013326548B2 (da) |
| BR (1) | BR112015007314B1 (da) |
| CA (1) | CA2887156C (da) |
| DK (1) | DK2903600T3 (da) |
| ES (1) | ES2928670T3 (da) |
| IL (1) | IL238064B (da) |
| MX (1) | MX374287B (da) |
| NZ (1) | NZ707328A (da) |
| RU (1) | RU2686108C2 (da) |
| SG (1) | SG11201502621XA (da) |
| TW (1) | TWI690322B (da) |
| WO (1) | WO2014053571A1 (da) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11273127B2 (en) * | 2014-05-06 | 2022-03-15 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for thermally stable multi-targeted antigens |
| EP3552615B8 (en) | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| AU2015357225B2 (en) * | 2014-12-01 | 2020-04-09 | Transgene Sa | Stable liquid vaccinia virus formulations |
| ES3011733T3 (en) | 2015-02-13 | 2025-04-08 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| US10512662B2 (en) | 2016-02-25 | 2019-12-24 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy |
| US10736962B2 (en) | 2016-02-25 | 2020-08-11 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors |
| WO2017160849A1 (en) * | 2016-03-14 | 2017-09-21 | Baylor College Of Medicine | Tc24-c4, a chagas disease vaccine antigen with improved stability and decreased aggregation |
| US10632184B2 (en) * | 2016-03-31 | 2020-04-28 | Takeda Vaccines, Inc. | Compositions and methods for stabilizing alphaviruses with improved formulations |
| EP3452081A1 (en) | 2016-05-04 | 2019-03-13 | Transgene SA | Combination therapy with cpg tlr9 ligand |
| TW201825674A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| EP3522920A2 (en) | 2016-10-10 | 2019-08-14 | Transgene SA | Immunotherapeutic product and mdsc modulator combination therapy |
| US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| CA3061678A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| US11052147B2 (en) | 2017-05-15 | 2021-07-06 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| JP7334124B2 (ja) | 2017-06-21 | 2023-08-28 | トランジェーヌ | 個別化ワクチン |
| AU2018378590A1 (en) * | 2017-12-05 | 2020-06-25 | Beacon Therapeutics Limited | Formulation optimization for viral particles |
| WO2019170820A1 (en) | 2018-03-07 | 2019-09-12 | Transgene | Parapoxvirus vectors |
| CN113528510A (zh) | 2018-06-29 | 2021-10-22 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
| CA3109432A1 (en) | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| EP3847246A1 (en) * | 2018-09-06 | 2021-07-14 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| EP3875119A4 (en) | 2018-10-30 | 2022-08-31 | The University of Tokyo | ONCOLYTIC VIRUS FOR CANCER THERAPY |
| WO2020136232A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | Immunosuppressive m2 protein |
| CN113453712A (zh) | 2018-12-28 | 2021-09-28 | 特兰斯吉恩股份有限公司 | M2缺陷型痘病毒 |
| JP7810554B2 (ja) | 2019-03-01 | 2026-02-03 | アケロイス バイオファーマ， インコーポレイテッド | 抗原特異的免疫細胞におけるｃｄ１６０機能をモジュレートする方法およびその使用 |
| CN113025633B (zh) | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| WO2021180943A1 (en) | 2020-03-12 | 2021-09-16 | Bavarian Nordic A/S | Compositions improving poxvirus stability |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| AU2023300419A1 (en) | 2022-07-01 | 2025-01-02 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
| CN115040656B (zh) * | 2022-07-05 | 2024-04-26 | 吉林惠康生物药业有限公司 | 狂犬疫苗冻干保护剂、应用和疫苗及其制备方法 |
| WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2076787A5 (en) * | 1970-01-28 | 1971-10-15 | Merieux Inst | Lyophilisation stabiliser - for viruses contg potassium phosphate lactose and albumin |
| US3915794A (en) * | 1973-02-09 | 1975-10-28 | Rit Rech Ind Therapeut | Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them |
| US4338335A (en) * | 1980-02-05 | 1982-07-06 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| AU568666B2 (en) * | 1983-08-25 | 1988-01-07 | Thomas, G. | Production of phosphates from alkali-proecessed phosphate rock |
| FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| GB8801338D0 (en) | 1988-01-21 | 1988-02-17 | Quadrant Bioresources Ltd | Preservation of viruses |
| CA2065023A1 (en) * | 1989-08-15 | 1991-02-16 | Brent Dorval | Stabilized vaccine compositions |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| WO1992015672A1 (en) | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
| FR2710536B1 (fr) | 1993-09-29 | 1995-12-22 | Transgene Sa | Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire. |
| CA2158935A1 (en) | 1993-10-12 | 1995-04-20 | Chiron Viagene, Inc. | Methods for preserving recombinant viruses |
| DE69535288T2 (de) | 1994-05-13 | 2007-04-05 | Thomas Jefferson University | Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren |
| EP0872249A4 (en) | 1995-03-17 | 2001-10-24 | Hisamitsu Pharmaceutical Co | GENE TRANSFER PREPARATION |
| FR2742756B1 (fr) * | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
| FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| ATE300954T1 (de) | 2001-12-10 | 2005-08-15 | Bavarian Nordic As | Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung |
| FR2855758B1 (fr) | 2003-06-05 | 2005-07-22 | Biomerieux Sa | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique |
| JP2007501223A (ja) * | 2003-08-05 | 2007-01-25 | フジ フォト フィルム ビー．ブイ． | 安定剤としての組換え又は合成ゼラチンのワクチン中の使用 |
| BRPI0417672A (pt) * | 2003-12-17 | 2007-03-20 | Wyeth Corp | processos para produzir composições de vìrus estáveis em armazenamento, composições de vìrus e imunogênicas |
| WO2005066333A1 (en) * | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
| CN100475268C (zh) | 2004-01-17 | 2009-04-08 | 上海三维生物技术有限公司 | 重组腺病毒冻干制剂及制备方法 |
| DK2486942T3 (da) * | 2004-11-24 | 2019-01-28 | Meda Pharmaceuticals Inc | Sammensætninger, der omfatter azelastin og fremgangsmåder til anvendelse deraf |
| TWI398272B (zh) * | 2005-03-08 | 2013-06-11 | Intervet Int Bv | 化學定義的安定劑 |
| JP2009507030A (ja) * | 2005-09-01 | 2009-02-19 | セルジーン・コーポレーション | ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用 |
| CN101351213B (zh) | 2005-09-07 | 2013-10-02 | 詹纳里克斯公司 | 使用表达gm-csf的痘病毒系统性治疗转移性癌和/或全身散布性癌 |
| JP5138601B2 (ja) * | 2005-11-21 | 2013-02-06 | サノフィ パストゥール リミテッド | 組換えウイルス安定化製剤 |
| CN101426810A (zh) | 2006-04-21 | 2009-05-06 | 特朗斯吉恩股份有限公司 | 基于hpv-18的乳头瘤病毒疫苗 |
| ES2611975T3 (es) | 2006-06-20 | 2017-05-11 | Transgene S.A. | Procedimiento para producir poxvirus y composiciones de poxvirus |
| WO2008017867A2 (en) * | 2006-08-10 | 2008-02-14 | Cipla Limited | Antiretroviral solid oral composition with at least one water insoluble polymer |
| KR20080084528A (ko) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| NZ584201A (en) | 2007-11-19 | 2012-06-29 | Transgene Sa | Poxviral oncolytic vectors comprising a defective f2l gene |
| BRPI0820576B1 (pt) | 2007-11-19 | 2021-10-19 | Transgène S.A. | Uso de um poxvírus oncolítico compreendendo um gene i4l e/ou f4l defectivo ou uma composição compreendendo o mesmo |
| NZ596595A (en) | 2009-05-12 | 2013-05-31 | Transgene Sa | Method for orthopoxvirus production and purification |
| BR112012002628B1 (pt) | 2009-08-07 | 2021-09-08 | Transgene Sa | Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes |
| US20110243988A1 (en) * | 2009-10-01 | 2011-10-06 | Aridis Pharmaceuticals | Methods and Compositions for Stabilization of a Virus Vaccine |
| US8557253B2 (en) * | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
| JP5960120B2 (ja) | 2010-03-31 | 2016-08-02 | スタビリテック リミテッド | ウイルス粒子の安定化 |
| RU2012144612A (ru) | 2010-04-15 | 2014-05-20 | Син Ниппон Байомедикал Лэборэтэриз, Лтд. | Способ и композиции для интраназальной доставки |
| TWI623618B (zh) | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
-
2013
- 2013-10-01 TW TW102135548A patent/TWI690322B/zh active
- 2013-10-02 US US14/433,142 patent/US10111947B2/en active Active
- 2013-10-02 AU AU2013326548A patent/AU2013326548B2/en active Active
- 2013-10-02 MX MX2015004290A patent/MX374287B/es active IP Right Grant
- 2013-10-02 BR BR112015007314-0A patent/BR112015007314B1/pt active IP Right Grant
- 2013-10-02 CN CN201380060245.7A patent/CN104797242B/zh active Active
- 2013-10-02 ES ES13776991T patent/ES2928670T3/es active Active
- 2013-10-02 KR KR1020157011647A patent/KR102181658B1/ko active Active
- 2013-10-02 CA CA2887156A patent/CA2887156C/en active Active
- 2013-10-02 NZ NZ707328A patent/NZ707328A/en unknown
- 2013-10-02 EP EP13776991.5A patent/EP2903600B1/en active Active
- 2013-10-02 SG SG11201502621XA patent/SG11201502621XA/en unknown
- 2013-10-02 WO PCT/EP2013/070590 patent/WO2014053571A1/en not_active Ceased
- 2013-10-02 JP JP2015535011A patent/JP6466332B2/ja active Active
- 2013-10-02 RU RU2015116539A patent/RU2686108C2/ru active
- 2013-10-02 DK DK13776991.5T patent/DK2903600T3/da active
-
2015
- 2015-03-31 IL IL238064A patent/IL238064B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20150250869A1 (en) | 2015-09-10 |
| JP2015531387A (ja) | 2015-11-02 |
| KR20150087206A (ko) | 2015-07-29 |
| RU2015116539A (ru) | 2016-11-27 |
| MX2015004290A (es) | 2016-01-20 |
| CA2887156A1 (en) | 2014-04-10 |
| EP2903600A1 (en) | 2015-08-12 |
| NZ707328A (en) | 2018-07-27 |
| IL238064B (en) | 2019-07-31 |
| KR102181658B1 (ko) | 2020-11-23 |
| AU2013326548A1 (en) | 2015-05-14 |
| TWI690322B (zh) | 2020-04-11 |
| US10111947B2 (en) | 2018-10-30 |
| MX374287B (es) | 2025-03-06 |
| IL238064A0 (en) | 2015-05-31 |
| BR112015007314B1 (pt) | 2023-05-09 |
| CA2887156C (en) | 2021-01-19 |
| AU2013326548B2 (en) | 2018-07-19 |
| HK1211206A1 (en) | 2016-05-20 |
| CN104797242B (zh) | 2019-10-01 |
| BR112015007314A2 (da) | 2017-08-15 |
| ES2928670T3 (es) | 2022-11-22 |
| TW201417820A (zh) | 2014-05-16 |
| CN104797242A (zh) | 2015-07-22 |
| RU2686108C2 (ru) | 2019-04-24 |
| WO2014053571A1 (en) | 2014-04-10 |
| EP2903600B1 (en) | 2022-08-31 |
| SG11201502621XA (en) | 2015-05-28 |
| JP6466332B2 (ja) | 2019-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269045A (en) | Aptamers and uses thereof | |
| DK3608325T3 (da) | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse | |
| DK2920313T3 (da) | Rekombinante adenovira og anvendelse deraf | |
| IL238064A0 (en) | A formulation containing a virus and its use | |
| DK2920197T3 (da) | Prolinlåste sammenhæftede peptider og anvendelser deraf | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| EP2870505A4 (en) | TRANSPARENT GLOSS AND GLOSS PROTECTION STRUCTURES | |
| DK2906684T3 (da) | T-celle-modificerende forbindelser og anvendelser deraf | |
| DK2850202T3 (da) | Fremgangsmåder og grupper | |
| DK2841429T3 (da) | Tetrazolinonforbindelser og anvendelse deraf som pesticider | |
| DK3196022T3 (da) | Trykningssystem og fremgangsmåde | |
| HRP20211423T4 (hr) | Formulacije enzalutamida | |
| DK2872419T3 (da) | Fordelingsbeholder og tilsvarende fremgangsmåde | |
| DK3077467T3 (da) | Sikkativsammensætning og anvendelse deraf | |
| BR112014000049A2 (pt) | pirrolotriazinas substituídas com hidroximelilarilo e sua utilização | |
| DK2745849T3 (da) | Polydeoxyribonukleotidsammensætning og anvendelser deraf | |
| DK2917181T3 (da) | Heteroarylderivater og anvendelser deraf | |
| DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
| DK3326642T3 (da) | Langtidsvirkende koagulationsfaktorer og brugen deraf | |
| DK3029038T3 (da) | Tetrazolinonforbindelse og anvendelse deraf | |
| CY2200004T2 (el) | Σκευασματα δαπτομυκινης και χρησεις αυτων | |
| DK3392252T3 (da) | Pyrimido-pyridazinonforbindelser og deres anvendelse | |
| DK2809669T3 (da) | Kondenserede pyrroldicarboxamider og deres anvendelse som farmaceutika | |
| DK2943460T3 (da) | 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf | |
| EP2808349A4 (en) | TRIBLOCK COPOLYMER AND USE THEREOF |